Actinium Pharmaceuticals, Inc. Employee Directory
Biotechnology ResearchNew York, United States51-200 Employees
Actinium Pharmaceuticals is a biotechnology company focused on targeted radiotherapies for cancer. Based in New York, New York, it develops radiopharmaceuticals for solid tumors and hematologic malignancies using a biology-driven approach that integrates tumor biology, translational medicine, and radiochemistry. Its pipeline covers solid-tumor therapeutics (ATNM-400 and Actimab-A with pan-tumor potential), Actimab-A as a backbone for AML and MDS in collaboration with the National Cancer Institute, and targeted conditioning agents such as Iomab-B and Iomab-ACT. ATNM-400 targets a novel antigen distinct from PSMA and has shown preclinical activity in metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer. Recent activity includes updates on ATNM-400 at the SNMMI 2026 Annual Meeting in May 2026.